Cmed announces that Aeras Global TB Vaccine Foundation has selected Timaeus system for electronic data capture and management

Horsham, UK , 1 December 2008

Adoption of Cmed’s Timaeus system establishes enhanced data management capture process for large-scale clinical trials

Cmed today announced that Aeras Global TB Vaccine Foundation has chosen Timaeus as its global intelligent electronic Data Acquisition and Management system. Aeras is a non-profit product development partnership developing and testing new vaccines against tuberculosis.

A genuinely single system which both captures and manages paper and electronic data, Timaeus is a “next generation” system with an architecture allowing wireless communication by all types of low and high bandwidth mobile (cell) phone technologies. Not only does it function with good internet connectivity via web eDC, but its ability to communicate over a small bandwidth means it is also able to cope with the restricted internet connectivity increasingly found in practice and communicate via mobile phone technologies with no performance penalty. This ability to communicate over an extremely low bandwidth means that Timaeus can operate in areas of interest to Aeras where internet access is not reliable.

“We are obviously delighted that Aeras has chosen our groundbreaking technology, Timaeus. It is doubly rewarding that it be an organisation like Aeras and we are particularly excited to be involved with them in an area both of scientific interest but, more importantly, of such potential social impact,” said David Connelly, CEO of Cmed. He added “we are looking forward to a long and worthwhile partnership”.